Added to YB: 2026-01-06
Pitch date: 2026-01-03
PALI [bullish]
Palisade Bio, Inc.
-23.81%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Market Cap
$372.5M
Pitch Price
$2.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
-32.08
P/E
-1.07
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Palisade Bio, Inc.
PALI (lotto play): Developing PALI-2108, colon-activated oral PDE4 inhibitor for UC/CD. Designed to minimize systemic side effects vs competitors like mufemilast. Phase 1 shows low systemic/high fecal activity. Phase 1b FSCD data Q1 2026, Phase 2 UC mid-2026. $138M raised Oct 2025. $550M MCap, potential $5-7B by end 2027.
Read full article (2 min)